Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Strong clinical data, but commercial and financial upside remain unproven and distant.

What the company is saying

Ascentage Pharma is positioning itself as a leading innovator in the treatment of chronic myeloid leukemia (CML) with its first approved product, olverembatinib. The company wants investors to believe that olverembatinib is not only clinically effective but also on the cusp of broader global adoption and commercial success. They highlight high response rates—specifically, a 91.3% complete cytogenetic response (CCyR) and a 60.9% major molecular response (MMR) at cycle 24 among 42 evaluable patients—as evidence of the drug’s efficacy. The announcement is framed around the presentation of these results at a major oncology conference, emphasizing the company’s scientific credibility and ongoing engagement with the global medical community. Prominently, Ascentage stresses the drug’s regulatory status in China, its inclusion in the National Reimbursement Drug List (NRDL), and the potential for a global partnership with Takeda, though this is only at the option agreement stage. The company’s tone is confident and forward-looking, using language that projects future success and clinical leadership, but it omits any discussion of current revenues, profits, or commercial sales. Notable individuals such as Yifan Zhai, MD, Chief Medical Officer, are cited to lend clinical authority, but there is no mention of major institutional investors or external validation from financial partners. This narrative fits a classic biotech IR strategy: focus on clinical milestones, regulatory progress, and partnership potential to maintain investor interest during the long development cycle. Compared to prior communications (which are not available for reference), there is no evidence of a shift in messaging, but the emphasis remains on future potential rather than realised commercial outcomes.

What the data suggests

The disclosed numbers are specific to clinical efficacy and safety, not financial performance. Among 42 evaluable patients, olverembatinib achieved a 91.3% CCyR and a 60.9% MMR at cycle 24, with best rates at study cutoff of 76.2% (CCyR) and 47.6% (MMR). The overall incidence of treatment-related adverse events was high at 89.4%, but most were low-grade and manageable, with some grade ≥3 hematologic toxicities that were recoverable. These results suggest the drug is effective in its target population, but the sample size is small and the data is interim, not final. There is no period-over-period comparison, so it is impossible to assess whether efficacy or safety is improving or declining over time. The announcement does not provide any financial data—no revenue, profit, cash flow, or commercial sales figures—so the financial trajectory of the company is entirely opaque. Prior targets or guidance are not referenced, and there is no indication of whether the company is meeting its own internal or external expectations. The quality of the clinical data is high, with clear definitions and numerically supported outcomes, but the absence of financial disclosures is a major gap. An independent analyst would conclude that while the clinical results are promising, there is no evidence yet of commercial traction or financial sustainability.

Analysis

The announcement presents positive clinical data with specific numerical results for olverembatinib in CML-CP, supporting some realised progress. However, a significant portion of the narrative is forward-looking, emphasizing future evidence accumulation, potential global partnerships, and anticipated clinical benefits without immediate commercial or financial impact. The language inflates the signal by projecting broader clinical and commercial success based on early-stage or interim data from a small patient cohort (42 evaluable patients). There is no disclosure of revenue, profit, or immediate financial outcomes, and the partnership with Takeda is only at the option agreement stage, not a binding license. While the clinical data is credible, the announcement overstates the near-term impact and implies broader success than is currently substantiated.

Risk flags

• ●The majority of claims are forward-looking, projecting future clinical and commercial success based on interim data from a small cohort of 42 patients. This matters because early-stage results often do not translate into broad regulatory or commercial success, and investors risk overestimating near-term value.
• ●There is a complete absence of financial disclosure—no revenue, profit, cash position, or commercial sales data are provided. This lack of transparency makes it impossible to assess the company’s financial health or runway, a critical risk for any biotech investment.
• ●The partnership with Takeda is only at the option agreement stage, not a binding license. While this signals some external interest, there is no guarantee that Takeda will exercise the option or that a commercial deal will materialize, leaving the global commercialization narrative highly speculative.
• ●The clinical data is based on a small sample size (42 evaluable patients), which limits statistical power and generalizability. Small studies are prone to variability and may not predict outcomes in larger, more diverse populations.
• ●All regulatory and reimbursement claims (e.g., NRDL inclusion, first-in-class status) are asserted without supporting documentation or numerical evidence. This matters because investors cannot independently verify these critical commercial milestones.
• ●The company is conducting three global registrational Phase III studies, which are capital-intensive and carry high execution risk. Delays, failures, or adverse findings in any of these trials could materially impact the company’s prospects.
• ●Geographic focus is heavily weighted toward China, with no evidence of commercial traction or regulatory progress in other major markets. This concentration exposes investors to country-specific regulatory, reimbursement, and market risks.
• ●Notable individuals cited are primarily internal (e.g., Chief Medical Officer), with no evidence of external institutional validation or investment. While internal expertise is necessary, the absence of third-party endorsement limits confidence in the company’s broader credibility.

Bottom line

For investors, this announcement signals that Ascentage Pharma has achieved promising clinical results with olverembatinib in a small, well-defined patient population, but has not yet demonstrated commercial or financial success. The company’s narrative is credible in terms of clinical efficacy and safety, as supported by the disclosed response rates and adverse event data, but the leap to global commercial leadership is not substantiated by current evidence. The Takeda option agreement is a positive sign of external interest, but it is not a binding deal and does not guarantee future revenue or market access outside China. To change this assessment, the company would need to disclose concrete financial metrics—such as revenue from olverembatinib, cash runway, or signed commercial agreements—as well as regulatory approvals in new markets. Key metrics to watch in the next reporting period include progress in the three Phase III trials (enrollment, interim results, regulatory submissions), any update on the Takeda agreement (option exercise, license signing), and the first disclosure of commercial sales or reimbursement uptake in China. At this stage, the information is worth monitoring but not acting on, as the signal is more about potential than realised value. The single most important takeaway is that while the clinical data is encouraging, the path to commercial and financial upside is long, uncertain, and currently unsupported by hard evidence.

Announcement summary

(NASDAQ:AAPG; HKEX:6855) Ascentage Pharma Group International announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP), presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Among 42 evaluable patients, olverembatinib achieved a complete cytogenetic response (CCyR) rate of 91.3% and a major molecular response (MMR) rate of 60.9% at cycle 24, with best CCyR and MMR rates of 76.2% and 47.6% at study cutoff. The overall incidence of treatment-related adverse events was 89.4%, most of which were manageable low-grade events, with some grade ≥3 hematologic toxicities observed but all recoverable through supportive treatment. Olverembatinib is the first third-generation BCR-ABL1 inhibitor approved in China and is currently approved in China for adult patients with tyrosine kinase inhibitor (TKI)-resistant CML-CP or accelerated-phase CML (CML-AP) harboring the T315I mutation, and adult patients with CML-CP resistant to and/or intolerant of first- and second-generation TKIs, with all approved indications now covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is conducting three global registrational Phase III studies to evaluate olverembatinib in multiple indications, including CML-CP, newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), with two of these studies cleared by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company has signed an exclusive option agreement to enter into an exclusive license agreement with Takeda for olverembatinib, which would grant Takeda global rights to develop and commercialize olverembatinib outside of mainland China, Hong Kong, Macau, and Taiwan, China, if the option is exercised. The company projects further accumulation of evidence from second-line and earlier-line settings to optimize the treatment pathway for patients with CML and deliver greater clinical benefit, longer survival, and improved quality of life.

Disagree with this article?